ANNX Annexon Biosciences
Price Chart
Executive Summary
Annexon reported Q1 2026 EPS of -$0.23, beating consensus of -$0.30 by 23%, with net loss narrowing to $44.1M from $54.4M a year ago. The company highlighted upcoming catalysts: Phase 3 GA data in Q4 2026, GBS BLA submission in 2026, and cash runway into H2 2027. The EPS beat and pipeline progress are positive, but the stock's reaction will hinge on clinical data readouts later this year.
Actionable Insight
The EPS beat and cash runway extension are positive, but the stock's next major catalyst is the Phase 3 ARCHER II GA data in Q4 2026. Traders should watch for any early data disclosures or regulatory updates on the GBS BLA. The narrow loss and strong balance sheet reduce near-term dilution risk.
Key Facts
- Q1 2026 EPS -$0.23 vs consensus -$0.30 (23% beat)
- Net loss $44.1M vs $54.4M YoY, narrowing 19%
- Cash, equivalents, and short-term investments $225M as of March 31, 2026
- Cash runway into H2 2027
- Phase 3 ARCHER II GA data expected Q4 2026
- GBS BLA submission planned in 2026
- R&D expenses fell to $35.8M from $48.2M YoY
Financial Impact
EPS beat of $0.07 vs consensus; net loss improved $10.2M YoY
Risk Factors
- Phase 3 ARCHER II GA trial may fail to meet endpoints
- GBS BLA submission could be delayed or rejected
- Cash runway only into H2 2027; may need future financing
- No approved products or revenue
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3290509 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
3d ago
|
ANALYST-UPGRADE
| $5.88 awaiting T+5 | awaiting T+5 | — | $4.71 (−19.90%) |
|
Jun 11, 2026
3d ago
|
Institutional Cluster
| $4.74 awaiting T+5 | awaiting T+5 | — | $4.71 (−0.63%) |
|
May 16, 2026
29d ago
|
ANALYST-UPGRADE
| $5.11 $5.02 | ▼ −1.76% | ▼ −0.93% | $4.71 (−7.83%) |
|
May 12, 2026
4w ago
|
ANALYST-UPGRADE
| $5.44 $4.96 | ▲ +8.82% | ▲ +8.90% | $4.71 (+13.42%) |
|
May 7, 2026
5w ago
|
Press Release
| $5.69 $5.37 | ▼ −5.62% | ▼ −7.09% | $4.71 (−17.22%) |
|
Apr 16, 2026
8w ago
|
ANALYST-UPGRADE
| $6.33 $6.06 | ▼ −4.27% | ▼ −5.25% | $4.71 (−25.59%) |
|
Apr 16, 2026
8w ago
|
ANALYST-UPGRADE
| $6.33 $6.06 | ▼ −4.27% | ▼ −5.25% | $4.71 (−25.59%) |
|
Mar 30, 2026
10w ago
|
Press Release
| $5.54 $6.05 | ▲ +9.21% | ▲ +5.26% | $4.71 (−14.98%) |
|
Mar 2, 2026
15w ago
|
Insider Cluster
| $5.52 $5.59 | ▲ +1.27% | ▲ +2.48% | $4.71 (−14.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access